https://orcid.org/0000-0001-8545-2660
Key Points
HSCT is recommended for patients achieving PR after initial treatment; patients with CR could adopt a wait-and-see strategy.
Prognostic risk models of adult patients with EBV-HLH with or without HSCT were developed by Lasso-Cox regression.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by aberrant immunological activity with a dismal prognosis. Epstein-Barr virus (EBV)–associated HLH (EBV-HLH) is the most common type among adults. Patients with EBV infection to B cells could benefit from rituximab, whereas lethal outcomes may occur in patients with EBV infection to T cells, nature killer cells, or multilineages. The necessity of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with EBV-HLH remains controversial. A total of 356 adult patients with EBV-HLH entered this study. Eighty-eight received HSCT under medical recommendation. Four received salvage HSCT. The 5-year overall survival (OS) rate for patients who underwent HSCT was 48.7% (vs 16.2% in patients who did not undergo transplantation; P < .001). There was no difference in OS between patients who received transplantation at first complete response (CR1) and those at first partial response (PR1) nor between patients at CR1 and CR2. Patients who received transplantation at PR2 had inferior survival. The rate of reaching CR2 was significantly higher in patients with CR1 than PR1 (P = .014). Higher soluble CD25 levels, higher EBV-DNA loads in plasma after HSCT, poorer remission status, more advanced acute graft-versus-host disease (GVHD), and the absence of localized chronic GVHD were associated with inferior prognosis (P < .05). HSCT improved the survival of adult EBV-HLH significantly. For patients who achieved PR after initial treatment, HSCT was recommended. A wait-and-see strategy could be adopted for patients who achieved CR after initial treatment but with the risk of failing to achieve CR2.
References
1.
Ponnatt
TS
, Lilley
Cullen M
, Mirza
Kamran M
. Hemophagocytic lymphohistiocytosis
. Arch Pathol Lab Med
. 2022
;146
(4
):507
-519
.2.
Janka
GE
. Familial hemophagocytic lymphohistiocytosis
. Eur J Pediatr
. 1983
;140
(3
):221
-230
.3.
Yao
S
, Wang
Y
, Sun
Y
, et al. Epidemiological investigation of hemophagocytic lymphohistiocytosis in China
. Orphanet J Rare Dis
. 2021
;16
(1
):342
.4.
El-Mallawany
NK
, Curry
CV
, Allen
CE
. Haemophagocytic lymphohistiocytosis and Epstein Barr virus: a complex relationship with diverse origins, expression and outcomes
. Br J Haematol
. 2022
;196
(1
):31
-44
.5.
Meng
GQ
, Wang
JS
, Wang
YN
, Wei
N
, Wang
Z
. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection
. Int Immunopharmacol
. 2021
;96
:107606
.6.
Sawada
A
, Inoue
M
. Hematopoietic stem cell transplantation for the treatment of Epstein-Barr virus-associated T- or NK-cell lymphoproliferative diseases and associated disorders
. Front Pediatr
. 2018
;6
:334
.7.
Trottestam
H
, Horne
A
, Aricò
M
, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol
. Blood
. 2011
;118
(17
):4577
-4584
.8.
Bergsten
E
, Horne
A
, Aricó
M
, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study
. Blood
. 2017
;130
(25
):2728
-2738
.9.
Machowicz
R
, Suarez
F
, Wiktor-Jedrzejczak
W
, et al. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
. Bone Marrow Transplant
. 2022
;57
(5
):817
-823
.10.
Song
Y
, Yin
Q
, Wang
J
, Wang
Z
. Autologous hematopoietic stem cell transplantation for patients with lymphoma-associated hemophagocytic lymphohistiocytosis
. Cell Transplant
. 2021
;30
:9636897211057077
.11.
Imashuku
S
, Morimoto
A
, Ishii
E
. Virus-triggered secondary hemophagocytic lymphohistiocytosis
. Acta Paediatr
. 2021
;110
(10
):2729
-2736
.12.
Yao
S
, He
L
, Zhang
R
, et al. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
. Ann Med
. 2023
;55
(1
):89
-100
.13.
Chinese Expert Consortium on Hemophagocytic lymphohistiocytosis
. Hematology Group of the Chinese Medical Association, pediatrics’ branch. Chinese expert consensus on the diagnosis and treatment of hemophagocytic syndrome
. Chinese Med J
. 2018
;98
(2
):91
-95
.14.
Hough
R
, Lopes
A
, Patrick
P
, et al. Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation
. Blood Adv
. 2022
;6
(7
):2414
-2426
.15.
He
L
, Wang
Y
, Suolitiken
D
, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults
. Hematol Oncol
. 2022
;40
(3
):390
-399
.16.
Yao
S
, Jin
Z
, He
L
, et al. Clinical features and prognostic risk prediction of non-Hodgkin lymphoma-associated hemophagocytic syndrome
. Front Oncol
. 2021
;11
:788056
.17.
Nikiforow
S
. Finding “intermediate” ground in transplant and HLH
. Blood
. 2018
;132
(13
):1361
-1363
.18.
Qin
Q
, Xie
Z
, Shen
Y
, et al. Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children: a systematic review and meta analysis
. Eur Rev Med Pharmacol Sci
. 2012
;16
(5
):672
-678
.19.
Cui
T
, Wang
J
, Wang
Z
. The outcome of induction therapy for EBV-related hemophagocytic lymphohistiocytosis: a model for risk stratification
. Front Immunol
. 2022
;13
:876415
.20.
Müller
LP
, Müller-Tidow
C
. The indications for allogeneic stem cell transplantation in myeloid malignancies
. Dtsch Arztebl Int
. 2015
;112
(15
):262
-270
.21.
Tsirigotis
P
, Byrne
M
, Schmid
C
, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
. Bone Marrow Transplant
. 2016
;51
(11
):1431
-1438
.22.
Horne
A
, Janka
G
, Maarten Egeler
R
, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis
. Br J Haematol
. 2005
;129
(5
):622
-630
.23.
Zhao
Y
, Li
Z
, Zhang
L
, et al. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis
. Br J Haematol
. 2020
;191
(3
):453
-459
.24.
Liu
P
, Pan
X
, Chen
C
, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults
. Blood
. 2020
;135
(11
):826
-833
.25.
Keenan
C
, Nichols
KE
, Albeituni
S
. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis
. Front Immunol
. 2021
;12
:614704
.26.
Vallurupalli
M
, Berliner
N
. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis
. Blood
. 2019
;134
(21
):1783
-1786
.27.
Allen
CE
, Marsh
R
, Dawson
P
, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies
. Blood
. 2018
;132
(13
):1438
-1451
.28.
Granados
JM
, Benichou
G
, Kawai
T
. Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance
. Curr Opin Organ Transplant
. 2015
;20
(1
):49
-56
.29.
Alvarez
M
, Pierini
A
, Simonetta
F
, et al. Infusion of host-derived unlicensed NK cells improves donor engraftment in non-myeloablative allogeneic hematopoietic cell transplantation
. Front Immunol
. 2020
;11
:614250
.30.
Ouachée-Chardin
M
, Elie
C
, de Saint Basile
G
, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients
. Pediatrics
. 2006
;117
(4
):e743
-e750
.31.
Collins
PJ
, Fox
CP
, George
L
, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells published correction appears in Blood. 2022 Nov 24;140(21):2306
. Blood
. 2021
;137
(2
):203
-215
.32.
Cassady
K
, Martin
PJ
, Zeng
D
. Regulation of GVHD and GVL activity via PD-L1 interaction with PD-1 and CD80
. Front Immunol
. 2018
;9
:3061
.33.
Maurer
K
, Soiffer
RJ
. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation
. Expert Rev Hematol
. 2023
;16
(12
):943
-962
.34.
Mo
XD
, Xu
LP
, Zhang
XH
, et al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome
. Bone Marrow Transplant
. 2015
;50
(1
):127
-133
.35.
Damania
B
, Kenney
SC
, Raab-Traub
N
. Epstein-Barr virus: biology and clinical disease
. Cell
. 2022
;185
(20
):3652
-3670
.36.
Yanagaisawa
R
, Matsuda
K
, Ohga
S
, et al. Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol
. Int J Hematol
. 2019
;109
(5
):612
-617
. Erratum in: Int J Hematol. 2019;109(5):629.37.
38.
Lindsay
J
, Yong
MK
, Greenwood
M
, et al. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation
. Rev Med Virol
. 2020
;30
(4
):e2108
.39.
Lindqvist
CA
, Christiansson
LH
, Simonsson
B
, Enblad
G
, Olsson-Strömberg
U
, Loskog
AS
. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies
. Immunology
. 2010
;131
(3
):371
-376
.40.
Griffin
G
, Shenoi
S
, Hughes
GC
. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy
. Best Pract Res Clin Rheumatol
. 2020
;34
(4
):101515
.41.
Andersson
U
. Hyperinflammation: on the pathogenesis and treatment of macrophage activation syndrome
. Acta Paediatr
. 2021
;110
(10
):2717
-2722
.42.
Yoshimori
M
, Nishio
M
, Ohashi
A
, et al. Interferon-γ produced by EBV-positive neoplastic NK-cells induces differentiation into macrophages and procoagulant activity of monocytes, which leads to HLH
. Cancers
. 2021
;13
(20
):5097
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal